AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Akari Therapeutics shares rise 20.62% intraday after acquiring Peak Bio's ADC platform and shifting focus to Trop2-targeted AKTX-101 development for multiple cancers.
ByAinvest
Tuesday, Dec 2, 2025 10:45 am ET1min read
Akari Therapeutics surged 20.62% intraday, as disclosed in its Form 10-Q filing on November 13, 2025, highlighting its focus on developing AKTX-101, a Trop2-targeting antibody-drug conjugate (ADC) for multiple solid tumors in preclinical stages. The company shifted strategic priorities to ADC development after acquiring Peak Bio’s ADC platform in November 2024, aiming to pursue partnerships for legacy projects and consolidate innovative pipeline resources.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet